Correction: An efficient metal free synthesis of 2-aminobenzothiozoles - a greener approach.

Correction for 'An efficient metal free synthesis of 2-aminobenzothiozoles - a greener approach' by Krithika Ganesh , , 2023, , 564-568, https://doi.org/10.1039/D2OB01981G.

An efficient metal free synthesis of 2-aminobenzothiozoles - a greener approach.

A facile one-pot, metal-free method for the synthesis of 2-aminobenzothiazoles was developed, which includes an initial reaction of electron-deficient 2-haloanilines with aromatic isothiocyanates and the subsequent intramolecular cyclization of the resulting thioureas through the SAr mechanism. This one-pot, atom-economical, robust, and scalable method avoids the use of reagents such as acid chlorides and Lawesson's reagent that are difficult to handle.

Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.

Objective: Mebendazole and other anti-parasitic drugs are being used off-prescription based on social media and unofficial accounts of their anti-cancer activity. The purpose of this study was to conduct a controlled evaluation of mebendazole's therapeutic efficacy in cell culture and in vivo models of ovarian cancer. The majority of ovarian cancers harbor p53 null or missense mutations, therefore the effects of p53 mutations and a mutant p53 reactivator, PRIMA-1 (APR246) on mebendazole activity were evaluated.

Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Current ovarian cancer maintenance therapy is limited by toxicity and no proven impact on overall survival. To study a maintenance strategy targeted at missense mutant p53, we hypothesized that the release of mutant p53 from mortalin inhibition by the SHetA2 drug combined with reactivation of mutant p53 with the PRIMA-1 drug inhibits growth and tumor establishment synergistically in a mutant-p53 dependent manner. The Cancer Genome Atlas (TCGA) data and serous ovarian tumors were evaluated for TP53 and HSPA9/mortalin status.

Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity.

Human fallopian tube fimbria secretory epithelial cells (hFTSECs) are considered an origin of ovarian cancer and methods for their culture from fallopian tube specimens have been reported. Our objective was to determine whether characteristics of the donors or surgeries were associated with the capacities of fimbria specimens to generate hFTSEC cultures or their immune profiles. There were no surgical complications attributable to fallopian tube removal.